Special Issue "Developing Role of Diagnostic Imaging and Nuclear Medicine Applications in Pancreatic Tumors"
Deadline for manuscript submissions: closed (31 March 2021).
Interests: medical imaging; nuclear medicine; positron emission tomography; magnetic resonance; diagnostic imaging; computed tomography; diagnostic radiology; cancer research; oncology; neuroscience
Interests: PET/CT; molecular imaging; radiopharmaceuticals; prostate cancer; PET/MRI
Special Issues, Collections and Topics in MDPI journals
Pancreatic neoplasm is a complex disease associated with a poor prognosis. Different histopathological types of pancreatic tumors have been reported, and the adenocarcinoma is the most common (more than 95%). At the time of diagnosis, patients often present in an advanced stage, since the disease is indolent and shows only non-specific symptoms like abdominal pain or weight loss. Therefore, an early and accurate diagnosis is of the utmost importance to determine the most effective therapy option and avoid futile surgery.
Pancreatic neuroendocrine tumors are rare, accounting for only 5% of all pancreatic tumors. However, their incidence is on the rise, most likely due to an improved awareness and incidental findings, as well as rapidly developing diagnostic methods.
Besides conventional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), molecular imaging with positron emission tomography (either PET/CT or PET/MRI) represents a powerful tool for detecting and evaluating pancreatic tumors in diverse disease settings. In this Special Issue we will contribute by collecting reviews or original data about theragnostic molecular imaging, in terms of both diagnosis (e.g., FDG, 68Ga-DOTA-peptides, and other radiopharmaceuticals for PET, 111In-Octeotride or similar tracers for SPECT, MRI and endoscopy) and therapy (e.g., 177Lu/90Y-DOTA-peptides).
Dr. Pierpaolo Alongi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neuroendocrine tumors
- radionuclide therapy